Latest Annual Report
Filed: 2026-02-13
Key Insights
- Vertex Pharmaceuticals reported strong revenue growth of 20% year-over-year, driven by increased sales of its core cystic fibrosis products.
- Research and development expenses increased by 15% as the company continued to invest in its pipeline of next-generation therapies, indicating a focus on innovation and future growth.
- The company provided guidance for continued double-digit revenue growth and margin expansion in the coming year, signaling confidence in its business outlook.